Lilly strengthens its oncology department with a new name

December 12, 2017 Off By Dino Mustafić

Eli Lilly said on Monday that Kimberly Blackwell, M.D., one of the USA’s leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018

Blackwell is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center. She also serves as the co-director of the Duke women’s cancer program, associate director for strategic relations for the Duke Cancer Institute, research scholar for Susan G. Komen, and senior strategist for the Duke Innovation and Entrepreneurship Program. She will report to Levi Garraway, M.D., Ph.D., senior vice president, Global Development & Medical Affairs of Lilly Oncology.

“We are pleased and honored to welcome Dr. Blackwell to Lilly,” said Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology. “She is highly regarded for her leadership in cancer research, especially metastatic breast cancer, where she has led programs that resulted in numerous groundbreaking regulatory approvals in the oncology sector.”

“Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop and advance novel treatments for people living with cancer.”